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Arsenic-induced human carcinogenesis
remains one of the most perplexing mecha-
nistic puzzles in contemporary toxicology.
Although current animal models of arsenic-
induced carcinogenesis are of equivocal bio-
logical relevance, convincing human
epidemiologic data have identiﬁed the skin,
lung, and bladder as targets of carcinogene-
sis caused by chronic exposure to arsenic
(Bates et al. 1992). Several potential
carcinogenic mechanisms have been pro-
posed, including inhibition of DNA repair
enzymes, tumor promoter-like induction of
proliferation, alteration of DNA methyla-
tion, and clastogenesis (Kitchin 2001).
Notwithstanding their lack of in vivo
potency in carcinogenesis assays, arsenic
compounds are potent toxicants both in
vitro and in vivo. Biological effects of in
vitro or in vivo exposure to arsenic include
apoptosis, protein ubiquitination, cellular
proliferation, oxidative stress, and enzyme
inactivation (Asmuss et al. 2000; Chen et
al. 2001; Hunter 2000; Kirkpatrick et al.
2003). Thus, arsenicals are clearly biologi-
cally active, but no definitive relationship
has been established that links carcinogene-
sis to speciﬁc toxic endpoints.
Toxicologists have been able to assemble
the key steps of the arsenic biotransformation
pathway by identifying the chemical species
of biotransformed arsenic. This pathway
includes several oxidation state changes,
successive oxidative methylations, and at
least four metabolites (Vahter 2002).
Notwithstanding the lack of specifically
identified carcinogenic mechanisms of
action, available evidence suggests that
arsenic biotransformation is likely to be key
to arsenic-induced disease. First, experi-
mental evidence suggests that arsenic
metabolism in humans could produce toxic
intermediates and certainly governs the in
vivo balance between chemical arsenic
species with high biological potency
and those with low biological potency.
Historically, methylation of arsenic has
been regarded as a detoxification mecha-
nism (Abernathy et al. 1999). Within that
historical context, detoxification typically
referred to the lower cytotoxic potency of
methylated arsenicals, namely monomethyl-
arsonic acid of valence V [MMA(V)] and
dimethylarsinic acid of valence V [DMA(V)],
compared with inorganic arsenic species. In
addition to the differential cytotoxicity
between inorganic arsenic and organic
arsenic in the +V valence state, there is dif-
ferential cytotoxicity between inorganic
arsenic in the +III valence state and inor-
ganic arsenic in the +V valence state. To
complicate matters further, more recently,
it has been shown that, as opposed to the
low potency of MMA(V) and DMA(V),
MMA(III) and DMA(III) are potent induc-
ers of apoptosis, cytosolic protein binding,
and epithelial hyperplasia (Thomas et al.
2001). In fact these methylated arsenic (III)
compounds may be the most potent toxi-
cants in the entire metabolic pathway.
Although no direct link exists between
arsenic-induced cytotoxicity and arsenic-
induced carcinogenesis, the differential bio-
logical activity of arsenic metabolites is
probably not restricted to cytotoxicity.
Thus, understanding arsenic metabolism is
likely to be key to a complete understand-
ing of arsenic carcinogenesis.
A second, equally compelling reason to
explore arsenic metabolism is the evidence
that the metabolism of arsenic may be
genetically influenced, with significant
interindividual variation in arsenic metabo-
lism among humans. Interspecies compar-
isons also suggest a genetic component to
arsenic metabolism. Comparison of nine
different strains of rats in which liver S9
fractions were exposed to inorganic arsenic
revealed a 2-fold difference between the
strain with the lowest rate of arsenic
methylation versus the strain with the
highest rate (Thomas et al. 2001). Parallel
experiments corroborated the S9 fraction
results with intact hepatocytes from the
nine strains. In experiments examining the
rate of formation of methylated arsenic in
hepatocytes taken from different human
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Individual variability in human arsenic metabolism has been reported frequently in the litera-
ture. This variability could be an underlying determinant of individual susceptibility to arsenic-
induced disease in humans. Recent analysis revealing familial aggregation of arsenic metabolic
proﬁles suggests that genetic factors could underlie interindividual variation in arsenic metabo-
lism. We screened two genes responsible for arsenic metabolism, human purine nucleoside phos-
phorylase (hNP), which functions as an arsenate reductase converting arsenate to arsenite, and
human glutathione S-transferase omega 1-1 (hGSTO1-1), which functions as a monomethylar-
sonic acid (MMA) reductase, converting MMA(V) to MMA(III), to develop a comprehensive
catalog of commonly occurring genetic polymorphisms in these genes. This catalog was gener-
ated by DNA sequencing of 22 individuals of European ancestry (EA) and 24 individuals of
indigenous American (IA) ancestry. In hNP, 48 polymorphic sites were observed, including 6
that occurred in exons, of which 1 was nonsynonymous (G51S). One intronic polymorphism
occurred in a known enhancer region. In hGSTO1-1, 33 polymorphisms were observed. Six
polymorphisms occurred in exons, of which 4 were nonsynonymous. In contrast to hNP, in
which the IA group was more polymorphic than the EA group, in hGSTO1-1 the EA group was
more polymorphic than the IA group, which had only 1 polymorphism with a frequency > 10%.
Populations representing genetic admixture between the EA and IA groups, such as Mexican
Hispanics, could vary in the extent of polymorphism in these genes based upon the extent of
admixture. These data provide a framework in which to conduct genetic association studies of
these two genes in relevant populations, thereby allowing hNP and hGSTO1-1 to be evaluated as
potential susceptibility genes in human arsenicism. Key words: arsenic, biotransformation,
European ancestry, indigenous American ancestry, hGSTO1-1, hNP, polymorphisms, SNP.
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http://dx.doi.org/ [Online 21 July 2003]donors, nearly a 10-fold difference was
observed (Styblo et al. 1999). Although
this difference could be due to conditions
surrounding donor organ condition or
assay conditions, it is interesting to note
that a comparison of several large studies
measuring the distribution of urinary
arsenic metabolites in humans exposed to
inorganic arsenic via drinking water
demonstrated a nearly 7-fold difference in
the fraction of urinary arsenic as MMA
(Vahter 2000). It is likely that some of this
variability is environmental; however, it is
possible that genetic variation may underlie
some of the variation in arsenic metabo-
lism. A role for genetic determinants of
arsenic biotransformation is supported in
recent work by Chung et al. (2002), in
which familial aggregation in the pattern of
urinary methylated arsenic metabolites was
demonstrated in Chilean families. 
A prerequisite in the evaluation of
potential genetic determinants of arsenic
metabolism is the development of a com-
prehensive catalog of genetic variation in
genes whose products are involved in
arsenic biotransformation. With such a cat-
alog, one can test individual or combina-
tions of polymorphic sites for association
with phenotypes related to arsenic biotrans-
formation, such as patterns of urinary
metabolites. This study represents the first
systematic polymorphism screening of two
genes involved in arsenic biotransformation,
human purine nucleoside phosphorylase
(hNP) and human glutathione S-transferase
omega 1-1 (hGSTO1-1). The products of
these genes function as arsenate reductase
and MMA, As(V) reductase, respectively
(Radabaugh et al. 2002; Zakharyan et al.
2001). Because a major focus of our labora-
tory is the local arsenic-affected population
[European ancestry (EA) individuals and
Mexican ancestry individuals], we devel-
oped this catalog using two populations of
subjects, EA subjects and indigenous
American ancestry (IA) subjects. Because
Mexican ancestry individuals represent
predominantly an admixture between
Europeans and indigenous Americans, these
two populations make up the primary
genetic background of the locally relevant
populations (Cerda-Flores et al. 2002)
Materials and Methods
Subjects
Anonymous DNA samples from healthy
individuals of self-reported ancestry were
obtained from the Coriell Institute
(Camden, NJ). Twenty-two samples from
individuals of EA and 24 samples from
individuals of IA were studied. EA individ-
uals were selected from unrelated Centre
d’Etude du Polymorphism Humain sam-
ples. The geographical origin of the IA
samples consisted of 5 samples from Peru,
9 samples from Mexico, 1 sample from
Ecuador, and 9 samples from Brazil. One
DNA sample isolated from chimpanzee
was also included in the study. These sam-
ples are commercially available; individual
sample identification and ordering infor-
mation are shown in the Supplemental
Material, Table 1.
Polymerase Chain Reaction
Genomic sequences for hNP and
hGSTO1-1 were accessed from the
UCSC Genome Browser (http://www.
genome.ucsc.edu) November 2002 freeze.
Polymerase chain reaction (PCR) ampli-
cons were designed to completely traverse
each gene, such that each amplicon was
approximately 900 bp long, and consecu-
tive amplicons overlapped each other by
approximately 200 bp. PCR reactions con-
tained 20 ng genomic DNA, 1 pmol of
each primer, 0.2 U taq polymerase (plat-
inum taq; Invitrogen, Carlsbad, CA) and
0.1 µM deoxynucleotide triphosphates in a
total volume of 10 µL. Specific reaction
conditions, including primer sequences, are
available from the authors.
Direct Polymerase Chain Reaction
Sequencing
PCR amplicons were prepared for cycle
sequencing by diluting them with water,
using a dilution range of 1:3–1:6, depend-
ing on the reaction yield determined by
agarose gel electrophoresis. Cycle-sequenc-
ing reactions were assembled using 0.4 µL
cycle-sequencing premix (BigDye, version
3.0; Applied Biosystems, Foster, CA),
1 pmol sequencing primer, 1.8 µL 5×
sequencing dilution buffer and 5 µL PCR
product in a ﬁnal volume of 10 µL. Cycle-
sequencing reactions were purified using
DNA-affinity magnetic beads (Agencourt
Biosciences, Beverly, MA). Purified
sequencing reactions were electrophoreti-
cally analyzed using a DNA Analyzer 3730
(Applied Biosystems).
Polymorphism Identiﬁcation 
and Analysis
Sequence chromatograms were processed
for base calling and assembly using the
phred, phrap, and Consed suite of software
programs (Ewing et al. 1998; Gordon et al.
1998). Initial polymorphism tagging was
performed using Polyphred, with a mini-
mum sequence quality of phred 25
(Nickerson et al. 1997). Potential polymor-
phic sites initially identified by Polyphred
were individually confirmed by visual
inspection of sequence traces. A criterion of
this visual inspection-conﬁrmation was that
the polymorphism must be observed in
multiple chromatograms from singleton
polymorphisms (polymorphisms occurring
in only one subject) or in multiple subjects.
For these confirmed polymorphic sites,
each genotype for each subject was also
confirmed by visual inspection of chro-
matograms. Polymorphic sites and associ-
ated subject-identified genotypes were
automatically output to a relational data-
base for further analysis, which included
the automated generation of ethnicity-
specific genotype frequencies, allele fre-
quencies, and goodness-of-fit tests for
Hardy-Weinberg equilibrium. Haplotypes
were inferred using a Gibbs-sampling algo-
rithm as implemented in the Phase soft-
ware program (Stephens et al. 2001).
Because the accuracy of statistically inferred
haplotype increases with increasing haplo-
type frequency, we used polymorphisms
with a minimum frequency [minor allele
frequency (MAF)] of 0.10 to define rela-
tively common haplotypes (Tishkoff et al.
2000). Pairwise linkage disequilibrium
(LD) was calculated as r2, a measure of the
product-moment correlation coefficient
(Devlin and Risch 1995). 
Gene Context of Polymorphisms
Each gene was annotated graphically using
the Artemis software program (Rutherford
et al. 2000). Annotations included exon
location, protein coding exon subset, read-
ing frame, and polymorphism site. Coding
region polymorphisms were evaluated for
codon changes resulting from polymor-
phisms and the predicted effect on amino
acid sequence.
Results
Glutathione S-Transferase
Omega 1-1, MMA(V) Reductase
Based on mapping data from the
November 2002 freeze of the Human
Genome Browser, hGSTO1-1 contains six
exons and extends for 12,551 bp of chro-
mosome 10, in banding region q25.1. This
is a region of low overall meiotic recombi-
nation, with a sex-averaged rate of 0.6 cen-
timorgan (cM)/megabase (Mb) (Kong et al.
2002). The summary of the results of poly-
morphism screening in hGSTO1-1 is
shown in Figure 1. Overall, 33 polymor-
phic sites were observed in the approxi-
mately 16,000 bases of genomic DNA that
we sequenced, including the gene itself, 5´
upstream, and 3´ downstream genomic
regions. The ﬂanking sequences of all poly-
morphisms are given in Supplemental
Material, Table 2, to allow unambiguous
identiﬁcation of polymorphisms. Complete
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site are shown in Supplemental Material,
Figure 1 (EA population), and Supple-
mental Material, Figure 2 (IA popula-
tion). Six polymorphisms occurred in
exons 4 and 6, 2 of which were in the
3´ untranslated region. The 4 remaining
polymorphisms were nonsynonymous,
resulting in two nonconservative amino
acid substitutions (A140D, E208K), one
amino acid deletion (E155del), and one
conservative amino acid substitution
(A236V). An interesting feature of these
data is the distribution of polymorphisms
between the EA and IA groups. Overall,
the IA group was minimally polymorphic.
The 14 polymorphisms observed in the IA
population had a mean heterozygosity of
0.085 ± 0.064 (mean ± SD). In contrast,
the mean heterozygosity of the 21 poly-
morphisms observed in the EA population
was 0.223 ± 0.195. In large part the
genetic polymorphisms of each group
were exclusive to that group. We observed
19 polymorphisms exclusive to the EA
group, 12 polymorphisms exclusive to the
IA group, and only 2 shared polymor-
phisms (668 and 8283). LD among high-
frequency (MAF > 0.10) polymorphisms
was observed spanning over 11,000 bp in
the EA group, with r2 values approaching
1.0 between sites 2609 and 12707. Of the
8 polymorphisms in the EA group with
MAF > 0.10, 7 (890, 1285, 2609, 6398,
8238, 10629, 12707) were in substantial
LD with each other, with r2 values between
0.60 and 1.0. LD in the IA group is
difficult to evaluate because of the low
frequency of the polymorphisms. Complete
pairwise LD plots for hGSTO1-1 are
shown in Supplemental Material, Figure 3
(EA group), and Supplemental Material,
Figure 4 (IA group). The lack of diversity
of the IA samples in this genomic region is
also reflected in the haplotype analysis,
shown in Tables 1 and 2. Considering only
relatively common haplotypes, here arbi-
trarily defined as those composed of poly-
morphisms with an MAF > 0.10, only two
haplotypes defined the entire IA popula-
tion. These haplotypes, in turn, were
defined by polymorphism 668, the only
polymorphism that exceeded this MAF
threshold. Thus, 84% of the chromosomes
studied carried the major allele for poly-
morphism 668. The remaining 16% of the
IA chromosomes carried the minor allele
for polymorphism 668. Despite having 8
polymorphisms exceeding the 0.10 MAF
threshold, the EA population was divided
into only three primary haplotypes, which
represented 93% of all EA chromosomes
(Table 2).The most common EA haplo-
type, GGG + AACT, was also the common
IA haplotype. The second most common
EA haplotype, AAA – GCAC, was entirely
absent from the IA population.
Purine Nucleoside Phosphorylase,
Arsenate Reductase
hNP contains six exons and occupies 7,636
bp of chromosome 14 in band region
q11.2. Substantially more meiotic recombi-
nation occurs in this region, compared
with hGSTO1-1, with a sex-averaged rate
of 3.7 cM/Mb (Kong et al. 2002). The
summary of the results of polymorphism
discovery in hNP is shown in Figure 2. The
flanking sequences of all polymorphisms
are given in Supplemental Material, Table
3, to allow unambiguous identification of
polymorphisms. Complete genotypes for
every individual at every site are shown in
Supplemental Material, Figure 5 (EA pop-
ulation), and Supplemental Material,
Figure 6 (IA population). Forty-eight poly-
morphisms were observed in the approxi-
mately 11,000 bases of DNA sequenced in
this genomic region. Six polymorphisms
occurred in exons, of which 1 (2544)
occurred in the 5´ untranslated RNA
(UTR) and 1 (9987) in the 3´ UTR. Of
the remaining 4 polymorphisms, 3 (5483,
5594, 8254) were synonymous, and 1
(5574) resulted in a conservative amino
acid substitution (G51S). In contrast to the
Toxicogenomics | Genetic polymorphism in arsenic-metabolizing genes
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668 –1859 5'  Genomic 45 16
890 –1637 5'  Genomic 33 0
1218 –1309 5'  Genomic 0 4
1285 –1242 5'  Genomic 36 0
1724 –803 5'  Genomic 2 0
1817 –710 5'  Genomic 0 4
2075 –452 5'  Genomic 0 2
2207 –320 5'  Genomic 9 0
2307 –220 5' Genomic 2 0
2609 82 Intron 1 34 0
6198 3671 Intron 2 0 2
6398 3871 Intron 2 34 0
7062 4535 Intron 2 0 4
7688 5161 Intron 3 2 0
7964 5437 Intron 3 0 2
8238 5711 Intron 3 43 4
8592 6065 Intron 3 2 0
8963 6436 Intron 3 0 2
9173 6646 Intron 3 9 0
9963 7436 Intron 3 0 2
9992 7465 Intron 3 0 4
10031 7504 Intron 3 2 0
10629 8102 Exon 4: A140D 34 0
10674 8147 Exon 4: E155del 5 0
10703 8176 Intron 5 2 0
10709 8182 Intron 5 7 0
11227 8700 Intron 5 0 5
12707 10180 Intron 5 33 0
13230 10703 Intron 5 2 0
14902 12375 Exon 6: E208K  5 0
14987 12460 Exon 6: A236V  0 4
15029 12502 Exon 6: 3' UTR  2 0
15035 12508 Exon 6: 3' UTR  0 8
0.50 0.25 0.50 0.25 ID
ATG
Offset Gene context Freq % Freq %
Minor allele frequency
European ancestry American ancestry
*
*
Figure 1. Summary of frequency and gene context of polymorphisms discovered in hGSTO1-1 in EA
(Europe) and IA (America) subjects. “ID” column indicates the polymorphism identiﬁcation number rela-
tive to the location in the consensus sequence, with the first base of the consensus numbered 1.
*Indicates insertion/deletion. “ATG offset” indicates the polymorphism location relative to the ﬁrst base
“A” of the ATG methionine initiation codon. “Freq %” is the MAF, graphically displayed in the column to
the right. Nonsynonymous SNPs are denoted by amino acid substitutions, e.g., A140D.
Table 1. hGSTO1-1 haplotypes: IA population.
Chromosomes (%) Haplotype ID 668
84.1 1 G
15.9 2 Asituation for hGSTO1-1, in the genomic
region of hNP, the IA group was more
polymorphic than was the EA group, with
mean heterozygosity values of 0.292 ±
0.127 for the IA group and 0.200 ± 0.132
for the EA group. Unlike hGSTO1-1,
where 94% of the polymorphisms were
exclusive to one group or the other, only
51% of all hNP polymorphisms were
exclusive to one group, with 11 polymor-
phisms exclusive to the EA group and 13
polymorphisms exclusive to the IA group.
Twenty-four polymorphisms were shared
by both groups. The contrast in overall
variability in the IA group between
hGSTO1-1 and hNP was evident in the
number of polymorphisms exceeding the
0.10 MAF threshold for haplotype analysis.
In contrast to hGSTO1-1 (in which the IA
group had 1 such polymorphism, whereas
the EA group had 8), in hNP the IA group
had 30 polymorphisms exceeding this
threshold, whereas the EA group had only
19. LD in both the IA and EA groups
was also more complex in hNP; in each
group the high-frequency polymorphisms
occurred in no less than three clusters, with
high LD within a cluster but low LD
between clusters (data not shown).
Complete pairwise LD plots for hNP are
shown in Supplemental Material, Figure 7
(EA group) and Supplemental Material,
Figure 8 (IA group). The results of haplo-
type analysis for hNP are shown in Tables
3 and 4. Haplotype analysis revealed a
greater complexity in the IA population
within the hNP genomic region than in
hGSTO1-1. Of the 48 IA chromosomes,
91.7% comprised ﬁve halotypes. Similarly,
the EA population chromosomes could
largely be described by five haplotypes,
which accounted for 81.8% of all EA chro-
mosomes studied.
Discussion
Genetic determinants of interindividual
variability in arsenic metabolism have been
speculated upon frequently in the litera-
ture, even before specific arsenic-metabo-
lizing genes were identified (Abernathy et
al. 1999; Vahter 1999, 2000). This project
focused on a thorough screening of the
first two characterized, arsenic-metabolic
genes, with the objective of producing a
catalog of commonly occurring polymor-
phisms in individuals of EA, IA, and by
inference, many individuals of Mexican
ancestry.
The genetics and molecular biology of
hNP have been studied extensively because
of the causative role of some nonsynony-
mous mutations in hNP in severe combined
immunodeficiency syndrome (SCID)
(Markert 1991; Sato and Wakabayashi
Toxicogenomics | Yu et al.
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Table 2. hGSTO1-1 haplotypes: EA population.
Chromosomes (%) Haplotype ID 668 890 1285 2609 6398 8238 10629 12707
47.7 3 G G G + A A C T
34.1 4 A A A – G C A C
11.4 5 A G G + A A C T
*
*
*
0.50 0.25 0.50 0.25 ID
ATG
Offset Functional context Freq % Freq %
Minor allele frequency
European ancestry American ancestry
208 –2432 5' Genomic 2 0
680 –1960 5' Genomic 2 0
1014 –1626 5' Genomic 34 48
1088 –1552 5' Genomic 14 31
1095 –1545 5' Genomic 16 12
1671 –969 5' Genomic 7 0
1748 –892 5' Genomic 20 15
2368 –272 5' Genomic 7 0
2544 –96 Exon1: 5' UTR 2  0
3207 567 Intron 1 18 15
3253 613 Intron 1 0 2
3679 1039 Intron 1 0 19
4008 1368 Intron 1 2 0
4303 1663 Intron 1 20 26
4557 1917 Intron 1 20 31
4594 1954 Intron 1 2 0
5328 2688 Intron 1 0 21
5483 2843 Exon 2: Syn 14 15
5574 2934 Exon 2: G51S 14 35
5594 2954 Exon 2: Syn 14 35
5703 3063 Intron 2 2 0
5766 3126 Intron 2 2 0
5802 3162 Intron 2 14 34
6037 3397 Intron 2 2 21
6272 3632 Intron 2 16 35
6386 3746 Intron 2 25 35
6563 3923 Intron 2 2 8
6586 3946 Intron 2 24 15
6631 3991 Intron 2 0 2
6688 4048 Intron 2 0 2
6938 4298 Intron 2 2 0
6986 4346 Intron 2 5 15
7036 4396 Intron 2 21 15
7424 4784 Intron 2 25 15
7717 5077 Intron 2 23 15
8254 5614 Exon 5: Syn 0 2
8477 5837 Intron 5 23 38
8506 5866 Intron 5 0 6
8538 5898 Intron 5 0 6
8845 6205 Intron 5 0 23
8883 6243 Intron 5 0 23
8912 6272 Intron 5 0 15
9293 6653 Intron 5 7 0
9400 6760 Intron 5 16 15
9987 7347 Exon 6: 3' UTR 16 15
10328 7688 3' Genomic 2 23
10461 7821 3' Genomic 0 15
10544 7904 3' Genomic 0 23
Figure 2. Summary of frequency and functional context of polymorphisms discovered in hNP in EA and IA
subjects. Syn, synonymous SNP. “ID” indicates the polymorphism identification number relative to the
location in the consensus sequence, with the ﬁrst base of the consensus numbered 1. *Indicates inser-
tion/deletion. “ATG offset” indicates the polymorphism location relative to the ﬁrst base “A” of the ATG
methionine initiation codon. “Freq %” is the MAF, graphically displayed in the column to the right.
Nonsynonymous SNP are denoted by amino acid substitutions, e.g., G51S.1998). Given the severe phenotype of
SCID, it is not difﬁcult to imagine that the
spectrum of genetic variations one would
observe in the general population would be
confined to a limited range of functional
changes in the protein. In fact for the 92
chromosomes that we studied, we observed
only one nonsynonymous change in the pre-
dicted amino acid sequence, a conservative
change of glycine to serine at residue 51.
The 5 remaining polymorphisms that
occurred in exons were either synonymous
or positioned in untranslated mRNA
regions. Although there is clear selection
pressure against amino acid polymorphism
in hNP, it is plausible that genetic polymor-
phism in gene regulatory regions could
occur, as such changes could manifest
themselves in a tissue-specific manner.
Thus, in the presence of a polymorphism
occurring in a gene regulatory region, a
lethal target tissue such as T lymphocytes
could be spared alterations in hNP gene
expression, while a tissue critical to arsenic
metabolism such as the liver could have
altered transcriptional activity. Two poly-
morphisms, 3207 and 3253, are present
within a region of intron 1 that has been
defined as an enhancer element; this ele-
ment may be absolutely necessary for gene
transcription (Jonsson et al. 1992, 1994).
No polymorphisms were observed in the
minimal promoter elements that have been
thus far defined for hNP (Jonsson et al.
1991).
hGSTO1-1 is a member of an atypical
class of glutathione transferases, with a bio-
chemical activity more closely resembling
glutaredoxins than other, more typical, glu-
tathione transferase enzymes (Board et al.
2000). Its involvement in biochemical
pathways in the human remains to be
fully characterized, but in addition to its
involvement in arsenic biotransformation,
hGSTO1-1 may include posttranslational
processing of interleukin-1β (Laliberte et
al. 2003). It is strongly expressed in sev-
eral tissues, including colon, heart, liver,
ovary, pancreas, prostate, and spleen (Yin
et al. 2001). 
Our analysis of hGSTO1-1 revealed a
higher degree of predicted amino acid
polymorphism than we observed in hNP.
As opposed to hNP, in which only 17% of
polymorphisms occurring in exons were
nonsynonymous, 67% (4 of 6) of exon
polymorphisms in hGSTO1-1 were non-
synonymous. Of these 4 nonsynonymous
polymorphisms, 3 were predicted to result
in nonconservative amino acid substitu-
tions. Only one of these nonconservative
substitutions occurred at above 0.10 MAF,
10629 (A140D), which occurred at 0.34
MAF in the EA population only. Because
the minimal regulatory region of hGSTO1-1
has not yet been characterized, we cannot
speculate as to which polymorphisms could
be occurring in regulatory regions. Not-
withstanding the amino acid diversity, per-
haps the most notable features of the
genetic evaluation of hGSTO1-1 are the
striking lack of polymorphism in the IA
group and the low complexity of the EA
group. One high-frequency polymorphism,
668, is common to both the IA group and
the EA group. Because the IA group proba-
bly derives from Asia, the appearance of
this polymorphism in both these geograph-
ically diverse groups suggests that this may
be an ancient polymorphism. Aside from
polymorphism 668, the IA group is
monomorphic with respect to polymor-
phisms above a 0.10 MAF. The EA group
has 7 additional polymorphisms above this
MAF threshold, but they are all in a high
degree of LD. This linked cluster of poly-
morphisms includes 1 nonsynonymous
polymorphism, 10629. Thus, for the IA
group, only 1 polymorphism, 668, is neces-
sary to define all common haplotypes. In
the EA group, only 2 polymorphisms, 668
and 1 polymorphism from the cluster of 7
linked polymorphisms, are necessary to
define all of the common haplotypes.
Several factors may explain the difference
in overall variation in hGSTO1-1 between
the IA and EA groups, including demo-
graphic events or, alternatively, selection
pressure on this genomic region. Perhaps of
greater significance is that for Mexican
individuals that are some admixture
between EA and IA, the extent to which an
individual might be polymorphic for
hGSTO1-1 is related to the degree of
European admixture in his/her ancestry.
Thus, genetic association studies of
hGSTO1-1 in Mexican Hispanics should
be carefully controlled for potential con-
founding by admixture.
To date, two studies have evaluated
polymorphisms in hGSTO1-1. Tanaka-
Kagawa et al. (2003), using polymorphism
data from the Single Nucleotide Poly-
morphism database (dbSNP; http://www.
ncbi.nlm.nih.gov/SNP/) studied 2 poly-
morphisms that were predicted to result in
nonsynonymous changes, A140D and
T217N. Substrate-dependent alterations
in the resultant polymorphic proteins were
observed. No validation of the presence or
frequency of these 2 polymorphisms in
human subjects was performed. Recently,
Whitbread et al (2003). reported func-
tional characterization of hGSTO1-1,
together with polymorphism screening and
validation in human subjects of three
ancestries, African, Australian (EA), and
Chinese. The authors based their polymor-
phism screening on existing polymor-
phisms in several databases. Through
successive tiers of validation, only 1 of 26
hGSTO1-1 polymorphisms originally
found in the databases was observed to
occur in any of the three ethnic groups.
This polymorphism resulted in a predicted
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Table 3. hNP haplotypes: IA population.
Chromosomes (%) Haplotype ID
33.3 1 A A A – A – G T C G C A A – T AAGTTATC GCGCCCG
16.7 2 G T A – A + T G C A T G G + AAGGTTAAT CCGCT CA
14.6 3 G A G + C – T T T A T G A + AGAACGGAC GTGCCCG
14.6 4 A A A – A – G T C G C A A – T AAGTTATC GCGCCT G
12.5 5 G T A – A – G T C G C A A – T AAGTTATC GCATCCG
1014
1088
1095
1748
3207
3679
4557
5328
5483
5574
5594
5802
6037
6272
6386
6688
6586
6986
8477
8883
7036
7424
7717
8845
8912
9400
9987
10328
10461
10544
Table 4. hNP haplotypes: EA population.
Chromosomes (%) Haplotype ID
47.7 6 A A A – A G C G C A – T A T T A T G C
9.1 7 A A A – A GCGCA–AGCGGA G C
9.1 8 G T A – A GCGCA–TATTATA T
9.1 9 G A G + A TTGCA–TGCG GA G C
6.8 10 G T A – C G C A T G + A A T T A T A T
1014
1088
1095
1748
3207
4557
5483
5574
5594
5802
6272
6386
6586
7036
7424
7717
8477
9400
9987nonsynonymous amino acid substitution,
A140D. In the course of the study, the
authors also discovered an insertion/dele-
tion polymorphism that caused a deletion
of residue E155 (E155del). Finally, the
authors generated expression constructs for
the three observed haplotypes of these two
polymorphisms and assayed the resultant
in vitro expressed protein function in enzy-
matic assays. Their functional analysis
demonstrated altered thiol transferase and
glutathione conjugation for the A140,
E155del haplotype. Our study also identi-
fied A140D (10629) and E155del
(10674), and we discovered 1 additional
nonsynonymous polymorphism in EA
subjects, E208K (14902), and 1 in IA sub-
jects, A236V (14987). The Whitbread
study (Whitbread et al. 2003) illustrates
two commonly encountered limitations of
in silico–based polymorphism screening,
namely, lack of validation of database
polymorphisms and incomplete characteri-
zation of the gamut of commonly occur-
ring polymorphisms in the population. In
this regard, it is important to note that, of
our 22 EA subjects, the same two subjects
that were heterozygous for E155del, were
also heterozygous for E208K. Thus, it is
possible that these 2 polymorphisms are in
substantial LD in EA subjects. As a result,
it is possible that, by testing the 155 dele-
tion, in the absence of the linked E208K
substitution (an A140, E155del protein vs.
an A140, E155del, E208K protein) the
expression constructs in the Whitbread
study do not accurately represent the com-
monly encountered hGSTO1-1 proteins,
at least in their EA Australian group. This
is particularly significant in light of the
nature of the predicted E208K substitu-
tion, in which an acidic amino acid is sub-
stituted by a basic amino acid. Further
testing is necessary to determine if these
polymorphisms occur together in other
ethnic groups.
Along with the EA and IA groups, we
sequenced both hNP and hGSTO1-1 in
one chimpanzee DNA sample (data not
shown). Chimpanzees, the closest non-
extinct primate relative of humans, do not
biotransform arsenic into methylated
species but do demonstrate arsenate reduc-
tase activity (Vahter et al. 1995; Wildfang
et al. 2001). Thus, it was not surprising
that we observed a high degree of protein
homology between humans and chim-
panzees in hNP and hGSTO1-1, with only
one amino acid difference between human
and chimpanzee hGSTO1-1, a conservative
substitution of isoleucine (human) for
valine (chimp) at residue 26. Two amino
acid differences were observed in hNP. At
residue 51, a site where we observed a
glycine to serine nonsynonymous polymor-
phism in the human subjects, the chimp
DNA sequence predicted a serine residue.
At residue 277, all of our subjects were
predicted to code for isoleucine, whereas
the chimp coded for valine. 
These data provide a functionally
annotated catalog of commonly occurring
genetic polymorphisms, in both protein
coding and potential gene regulatory
regions, in two important xenobiotic-
metabolizing genes in populations that
make up the genetic background of a sub-
stantial portion of Europe and the
Americas. The combination of functional
polymorphisms, clusters of linked poly-
morphisms, and haplotypes provide an
essential framework from which to design
genetic association studies to test key phe-
notypes related to arsenic biotransforma-
tion, such as urinary arsenic metabolic
proﬁle and susceptibility to arsenic-induced
disease.
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